Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 3, 2025
Robotic Surgery Is No Longer the Future—It's the Revenue Engine of Healthcare | MarketsandMarkets™.
Delray Beach, FL, July 03, 2025 (GLOBE NEWSWIRE) -- What’s powering a $33.8 billion opportunity? The robotic surgery market is on a fast lane, expected to surge from USD 16.0 billion in 2024 to USD 33.8 billion by 2029, at a robust CAGR of 16.1%. This …
PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) received on July 2, 2025, an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely …
Only Transparency and Accountability Can Save CERN: Stop Billions in Waste, Unlock Life-Saving Innovations
DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- The Crosetto Foundation for the Reduction of Cancer Deaths, an accredited nonprofit, issues an “urgent appeal to Members of the European Parliament and national parliaments: freeze funding for CERN’s Phase 2 …
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)…
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July …
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) …
HUTCHMED to Announce 2025 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 …
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone payment associated with advance of drug candidate Oxford, …
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for …
Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight …
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date …
Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et la contrepartie totale en espèces potentielles …